Predicting ARIA incidence due to anti-amyloid therapy for Alzheimer’s disease with multimodal risk modeling frameworks

Abstract Amyloid-related imaging abnormalities (ARIA) are potentially serious adverse side effects of amyloid-targeting treatment (ATT) for Alzheimer’s disease. Pre-screening patients to identify high-risk cohorts based on biological and imaging biomarkers could enable more personalized treatment plans and reduce unnecessary risk and costs. Risk factors are well-characterized from trials, and anti-amyloid therapy is increasingly recommended. There is hence a growing need for pretreatment risk stratification tools. Clinically useful tools require individualized predictive models, but existing risk modeling is limited to pharmacokinetic analyses and frameworks using a small handful of pre-specified factors. None integrate multimodal pre-treatment data, use foundation models, or show validation in real-world cohorts. We propose a framework combining multimodal foundation model architectures (imaging, tabular, vision-language) with ARIA-specific design choices, including prediction heads separating ARIA-E and ARIA-H, severity grading, time-to-event modeling, and APOE -stratified monitoring decisions, validated through real-world hospital data in patients receiving ATT.

Authors

Institutions

Publication Details

Journal
npj Dementia
Published
2026-11-13
DOI
https://doi.org/10.1038/s44400-026-00138-z
Primary Topic
Alzheimer's disease research and treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Predicting ARIA incidence due to anti-amyloid therapy for Alzheimer’s disease with multimodal risk modeling frameworks

Lawren A. VandeVrede, Andreas M. Rauschecker, Michael F. Romano, Duygu Tosun et al.
3 links
npj Dementia
Alzheimer's disease research and treatments
article

Predicting ARIA incidence due to anti-amyloid therapy for Alzheimer’s disease with multimodal risk modeling frameworks

Lawren A. VandeVrede, Andreas M. Rauschecker, Michael F. Romano, Duygu Tosun, Ali Shah Tejani, Jinchi Wei, Evan S Bloch, Luke Bonham
article en

Abstract

Abstract Amyloid-related imaging abnormalities (ARIA) are potentially serious adverse side effects of amyloid-targeting treatment (ATT) for Alzheimer’s disease. Pre-screening patients to identify high-risk cohorts based on biological and imaging biomarkers could enable more personalized treatment plans and reduce unnecessary risk and costs. Risk factors are well-characterized from trials, and anti-amyloid therapy is increasingly recommended. There is hence a growing need for pretreatment risk stratification tools. Clinically useful tools require individualized predictive models, but existing risk modeling is limited to pharmacokinetic analyses and frameworks using a small handful of pre-specified factors. None integrate multimodal pre-treatment data, use foundation models, or show validation in real-world cohorts. We propose a framework combining multimodal foundation model architectures (imaging, tabular, vision-language) with ARIA-specific design choices, including prediction heads separating ARIA-E and ARIA-H, severity grading, time-to-event modeling, and APOE -stratified monitoring decisions, validated through real-world hospital data in patients receiving ATT.

npj DementiaVol. 2(1)
University of California, San Francisco (US), University of California, Berkeley (US)
Good health and well-being
Alzheimer's disease research and treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon